6,000
Participants
Start Date
September 26, 2022
Primary Completion Date
March 1, 2029
Study Completion Date
March 1, 2029
SGLT2 inhibitor
Empagliflozin, dapagliflozin, or canagliflozin
GLP-1 receptor agonist
Dulaglutide, liraglutide, semaglutide
RECRUITING
Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University, New York
RECRUITING
Johns Hopkins School of Medicine, Baltimore
RECRUITING
Duke University Hospital, Durham
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Vanderbilt University Medical Center, Nashville
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Essentia Health, Duluth
RECRUITING
University of Missouri-Columbia, Columbia
Patient-Centered Outcomes Research Institute
OTHER
Brigham and Women's Hospital
OTHER